← All reports

The 'bespoke' mRNA vaccine significantly reduces the risk of melanoma recurrence or death in clinical trials.

HealthcareTechnologyOct 23, 2026score 0.362 posts · 0 replies across 2 instances
A clinical trial shows a 'bespoke' mRNA vaccine significantly reduces melanoma recurrence or death, marking a potential shift in personalized cancer treatment. The post includes a cautious acknowledgment of scientific limitations.

Claims

The 'bespoke' mRNA vaccine significantly reduces the risk of melanoma recurrence or death in clinical trials.
Parent: HealthcareEntity: mRNA vaccineSub-entity: melanoma treatmentImpact: positiveDate: Oct 23, 2026Target: Effectiveness of the mRNA vaccine in treating melanoma

Source posts

@[email protected]
All the usual caveats about science, but omg: ‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows https://www.theguardian.com/society/2026/oct/23/mrna-vaccine-melanoma-cancer-breakthrough-australia
4 boosts · 5 favs · 0 replies · Oct 23, 2026
@[email protected]
‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows https://www.theguardian.com/society/2026/oct/23/mrna-vaccine-melanoma-cancer-breakthrough-australia Trial results represent ‘foundational shift’ in approach to cancer, allowing scientists to harness immune system in more personalised way
1 boosts · 1 favs · 0 replies · Oct 23, 2026